Moderna Inc. (MRNA:NSD) Analysts are bearish on stock with Underperform rating

STA research maintains Moderna as underperform at $70 target.

Based on the Moderna stock price history forecasts from 10 analysts, the average analyst target price for Moderna Stock Price History is USD 159.76 over the next 12 months. Moderna Inc.’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Moderna Stock Price History is Bullish, which is based on 10 positive signals and 4 negative signals. At the last closing, Moderna Inc.’s stock price was USD 166.89. Moderna Inc.’s stock price has changed by -4.35% over the past week, +38.86% over the past month and -48.03% over the last year.

Using messenger RNA therapies and vaccines, Moderna, Inc., a biotechnology firm, discovers, develops, and sells them for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular disorders, and autoimmune diseases in the United States, Europe, and other countries. Incorporated in 2010, Moderna, Inc. is based in Cambridge, Massachusetts.

 

What we like:

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk-adjusted returns

This stock has performed well, on a risk-adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered a better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered a better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered a better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth compared to its sector in the previous 5 years.

Superior Revenue Growth

This stock has shown top quartile revenue growth compared to its sector in the previous 5 years.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

 

What we don’t like:

High volatility

The total returns for this company are volatile and above the median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers’ median on a price-to-book value basis.

Overpriced on a cash flow basis

The stock is trading high compared to its peers on a price-to-cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering buying.

Overpriced on a free cash flow basis

The stock is trading high compared to its peers on a price-to-free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering buying.